APLS Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of Apellis Pharmaceuticals Inc(APLS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Apellis Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q3
2025-10-30
Pre-Market
1.03
1.67
+62.14
409.16M
458.58M
+12.08
-31.01
-31.88
FY2025Q2
2025-07-31
Pre-Market
-0.44
-0.33
+25.00
188.65M
178.49M
-5.38
+17.58
+27.37
FY2025Q1
2025-05-07
Pre-Market
-0.36
-0.74
-105.56
194.88M
166.80M
-14.41
-5.91
-8.37
FY2024Q4
2025-02-28
Pre-Market
-0.39
-0.29
+25.64
197.91M
212.53M
+7.38
-3.27
-2.62
FY2024Q3
2024-11-05
Pre-Market
-0.32
-0.46
-43.75
199.82M
196.83M
-1.50
-1.70
+3.57
FY2024Q2
2024-08-01
-
-0.33
-0.28
+15.15
191.31M
199.69M
+4.38
-9.09
-15.18
FY2024Q1
2024-05-07
-
-0.54
-0.54
-
164.26M
172.33M
+4.91
-10.06
-11.88
FY2023Q4
2024-02-27
-
-0.66
-0.73
-10.61
143.59M
146.38M
+1.94
-3.32
-9.90
FY2023Q3
2023-11-01
-
-0.84
-1.17
-39.29
99.05M
110.40M
+11.45
+2.55
-2.79
FY2023Q2
2023-07-31
-
-1.35
-1.02
+24.44
71.12M
94.97M
+33.53
-19.58
-23.39
APLS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Apellis Pharmaceuticals Inc reported performance for FY2025Q3, announced on 2025-10-30. The company achieved an EPS of 1.67, compared to analyst estimates of 1.03 by 62.14% . Revenue for the quarter reached 458.58M compared to expectations of 409.16M by 12.08% .
The stock price reacted with a -31.01% one-day change and a -31.88% five-day change following the earnings release. These movements reflect market reaction in Apellis Pharmaceuticals Inc growth trajectory and strategic initiatives.
APLS Earnings Forecast
Looking ahead, Apellis Pharmaceuticals Inc(APLS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 201.11M and an EPS of -0.38.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 6.03%, while EPS estimates have been Revise Downward by -176.92%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -5.09% . These revisions correlate with a 3.11% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Apellis Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between APLS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+6.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-176.92%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-5.09%
In Past 3 Month
Stock Price
Go Up
+3.11%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:990.98M
--
EPS Estimate-Annual FY 2025:0.26
—
Stock Price24.56
APLS Revenue and EPS Performance: A Historical Perspective
Apellis Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-30,Pre-Market):
EPS: 1.67 (Actual) vs.1.03 (Estimate) (62.14%)
Revenue: 458.58M (Actual) vs. 409.16M (Estimate) (12.08%)
Price Reaction:-31.01%(1-Day), -31.88%(5-Day)
FY2025Q2 (2025-07-31,Pre-Market):
EPS: -0.33 (Actual) vs.-0.44 (Estimate) (25.00%)
Revenue: 178.49M (Actual) vs. 188.65M (Estimate) (-5.38%)
Revenue: 166.80M (Actual) vs. 194.88M (Estimate) (-14.41%)
Price Reaction:-5.91%(1-Day), -8.37%(5-Day)
Earnings Reaction
The chart below shows how APLS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, APLS sees a +12.10% change in stock price 10 days leading up to the earnings, and a +3.17% change 10 days following the report. On the earnings day itself, the stock moves by -6.38%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 3.57% on the day following the earnings release and then changed by -4.44% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of APLS's latest earnings report for FY2025Q3?
APLS reported its FY2025Q3 earnings on 2025-10-30, showcasing a revenue of 458.58M against an estimate of 409.16M, resulting in a 12.08% surprise. The EPS was 1.67, surpassing the expected 1.03 by 62.14% . The stock experienced a -31.01% price change on the earnings day and a -31.88% change over the next five days, reflecting market reactions to the results.
How did APLS's stock price react after the FY2025Q3 earnings release?
Following APLS's FY2025Q3 earnings announcement on 2025-10-30, the stock price moved by -31.01% on the day of the release. Over the subsequent five days, it saw a -31.88% change. Historically, APLS's stock price tends to shift by an average of +12.10% in the 10 days leading up to earnings and +3.17% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for APLS for 2025/Q4?
For 2025/Q4, analysts estimate APLS’s annual revenue to reach 201.11M, while the EPS is projected at -0.38. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 6.03% and EPS estimates Revise Downward by -5.09% over the past three months, indicating analyst expectation in the company’s performance.
How does APLS's stock price correlate with earnings forecast revisions?
The correlation between APLS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 6.03%, while EPS estimates moved Revise Downward by -5.09% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from APLS's next earnings report?
Based on historical trends, APLS's stock price typically moves by +12.10% in the 10 days before its earnings and +3.17% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.38 and revenue of 201.11M.
What is the sentiment in Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Summary?
The earnings call reflects a mixed sentiment. While there are positive developments like the expected transition of patients to commercial growth and new trials, concerns exist regarding revenue segmentation and the timeline for new product launches. The Q&A session reveals uncertainties about market growth and product availability, which tempers enthusiasm. Given the lack of strong catalysts or significant new partnerships, the overall sentiment is neutral, with no clear indication of a strong positive or negative stock price movement.
